Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab vs Atezolizumab in extensive stage small cell lung cancer
NCT05468489Phase 3Active, not recruiting
- Sponsor
- Henlius
- Start
- Nov 2022
- Primary completion
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of serplulimab in small cell lung cancer (SCLC) (2 arms), sponsored by Henlius. Primary endpoint: Overall Survival at 24 months. Started Nov 2022; status: active, not recruiting.
02
Drugs
serplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05468489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05468489.